You have been added you to our distribution list. You’ll hear from us shortly.
To report an adverse event, please click here.
Additional medical information about any of Correvio’s products could be requested at firstname.lastname@example.org.
Correvio to Present at the Piper Jaffray 31st Annual Healthcare Conference
Correvio Announces Presentation of New BRINAVESS™ Spectrum Data at the American Heart Association 2019 Annual Meeting
Correvio Reports Third Quarter 2019 Financial Results
Correvio to Report Third Quarter 2019 Financial Results
Correvio Announces FDA Advisory Committee Meeting to Review BRINAVESS for Recent Onset Atrial Fibrillation
Correvio to Present at the 2019 Cantor Global Healthcare Conference
Correvio Highlights FDA Acceptance of United Therapeutics’ TREVYENT New Drug Application
Correvio to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Correvio Announces Presentation of BRINAVESS® Spectrum Data at the European Society of Cardiology 2019 Congress
Correvio Reports Second Quarter 2019 Financial Results
Copyright 2018 Correvio Pharma Corp. All rights reserved.
By following this link you will be leaving the correvio.com website. Please note that Correvio does not take responsibility for the content displayed on other websites: